Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc., filed a statement of changes in beneficial ownership on August 21, 2026, disclosing a sale of common stock on August 19, 2026, in connection with the vesting of Restricted Stock Units.

Key Highlights

  • Reporting person: Patrick Burnett, EVP and Chief Medical Officer of Arcutis Biotherapeutics, Inc.
  • Transaction date: August 19, 2026, with the filing signed on August 21, 2026.
  • Shares disposed: 1,697 shares of common stock sold at $27 per share, coded as a disposition (D).
  • Purpose of sale: According to the filing, the shares were sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
  • Remaining ownership: Following the transaction, Burnett directly beneficially owned 117,592 shares of common stock.
  • Issuer trading symbol: Arcutis Biotherapeutics trades on NASDAQ:ARQT.

Details of Patrick Burnett's August 2026 Share Disposition at Arcutis Biotherapeutics

According to the filing, Patrick Burnett, serving as EVP and Chief Medical Officer at Arcutis Biotherapeutics, Inc., a biotherapeutics company headquartered at 3027 Townsgate Road, Suite 300, Westlake Village, California, disposed of 1,697 shares of common stock on August 19, 2026. The transaction was reported using code "S" under Table I, indicating a sale of non-derivative securities. The filing recorded the per-share price as $27, and the ownership form was listed as direct (D).

The filing includes an explanation noting that "the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units." No discretionary open-market sale is indicated by the filing's characterization of the transaction. Following this disposition, Burnett's direct beneficial ownership in Arcutis Biotherapeutics common stock stood at 117,592 shares, according to the filing. The form was filed by one reporting person and was signed by Latha Vairavan as Attorney-in-Fact for Patrick Burnett on August 21, 2026.

No derivative securities transactions were reported in Table II of this filing. The filing does not indicate any amendment to a prior filing, and no deemed execution date was listed for the reported transaction.

What Was Disclosed

The filing disclosed that Arcutis Biotherapeutics Chief Medical Officer Patrick Burnett sold 1,697 shares of common stock at $27 per share on August 19, 2026, solely to satisfy tax withholding obligations upon Restricted Stock Unit vesting, leaving him with 117,592 directly held shares.